LITT and Pembrolizumab in Recurrent Brain Metastasis

Conditions:   Melanoma;   Non-small Cell Lung Carcinoma (NSCLC);   Renal Cell Carcinoma (RCC);   Brain Metastases Intervention:   Combination Product: LITT + Pembrolizumab Sponsors:   University of Florida;   Monteris Medical Corporation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials